A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT).

Trial Profile

A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Valsartan (Primary) ; Nateglinide
  • Indications Cardiovascular disorders; Glucose intolerance; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms NAVIGATOR
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2017 Results published in the American Heart Journal
    • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 30 Aug 2010 A late-breaking analysis reviewing 21 trials, including NAVIGATOR, was presented at the European Society of Cardiology (ESC) Congress, according to a European Society of Cardiology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top